Needham & Company increased its target price and gave a buy rating for ICU Medical.
2 reports, 1 independent
Updated Mon 00:00
No new developments lately
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Needham & Company increased its target price and gave a buy rating for ICU Medical.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Needham & Company
American independent investment bank and asset management firm
-
ICU Medical
California-based company that develops, manufactures, and sells medical technologies used in vascular therapy, oncology, and critical care applications
Nothing else this week.
Related events
- Needham & Company cut its target price and set a buy rating for Applied Optoelectronics, while Raymond James Financial reiterated an outperform rating. MarketBeat provided consensus data.
- Citigroup reissued a market outperform rating and Needham lifted its target price for Alkami Technology Inc.
- Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
- Needham & Company raised its price target and issued a buy rating for Unusual Machines, Inc., while insider transactions were also disclosed via SEC filings.
- Needham & Company cut its price target and set a buy rating for Endava, while CLSA also set a $5.00 price objective.